Devita, Hellman, and Rosenberg's Cancer

LWBK1006-42 LWW-Govindan-Review December 12, 2011 20:38

CHAPTER 42 STEM CELL

TRANSPLANTATION

MARK A. SCHROEDER•PETER WESTERVELT

DIRECTIONS Each of the numbered items below is followed by lettered answers. Select the

ONE lettered answer that is BEST in each case unless instructed otherwise.

QUESTIONS

Question 42.1. The curative potential of allogeneic hematopoietic stem cell transplanta-

tion (HSCT) may be derived from which of the following:

A. High-dose chemotherapy

B. Graft-versus-leukemia (GVL) effect

C. Graft-versus-host effect

D. A and B

Question 42.2. The allogeneic transplant conditioning regimen serves to achieve which

of the following:

A. Provide immunosuppression to prevent rejection

B. Provide immunosuppression to prevent graft-versus-host disease

(GVHD)

C. Eradicate malignant cells

D. A and C

Question 42.3. Which of the following regimens is considered myeloablative?

A. Cyclophosphamide 60 mg/kg/d intravenously (IV)×2 days plus

1200 cGy total body irradiation (TBI)

B. Cyclophosphamide 60 mg/kg/d IV×2 days plus busulfan 3.2 mg/kg/d

IV×4 days

C. Fludarabine 30 mg/kg/d IV ×5 plus busulfan 3.2 mg/kg/d IV

×2 plus antithymocyte globulin (ATG) 2.5 mg/kg/d IV× 4

D. A and B

Corresponding Chapters inCancer: Principles & Practice of Oncology,Ninth Edition: 154 (Autologous Stem Cell

Transplantation) and 155 (Allogeneic Stem Cell Transplantation).

525